Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma

BACKGROUND: Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death,...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Nanumi, Baghdadi, Muhammad, Ishikawa, Kozo, Endo, Hiraku, Kobayashi, Takuto, Wada, Haruka, Imafuku, Keisuke, Hata, Hiroo, Seino, Ken-ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836392/
https://www.ncbi.nlm.nih.gov/pubmed/29515691
http://dx.doi.org/10.1186/s41232-018-0060-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836392/
https://www.ncbi.nlm.nih.gov/pubmed/29515691
http://dx.doi.org/10.1186/s41232-018-0060-2

Ejemplares similares